News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Aventis Pharma Obtains Additional Approval for Taxoid Antitumor Agent TAXOTERE Injection
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo (JCN) - Aventis Pharma of the sanofi-aventis Group announced on August 19 that it has obtained additional approval for TAXOTERE Injection, its proprietary taxoid antitumor agent, from the Ministry of Health, Labor and Welfare as of August 18.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Sanofi US
Sanofi (France)
MORE ON THIS TOPIC
Regulatory
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection
February 26, 2026
·
1 min read
·
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
·
2 min read
·
Heather McKenzie
FDA
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta
February 25, 2026
·
6 min read
·
Joshua R. Mansbach
Vaccines
FDA’s Makary Backs mRNA Vaccines but Says Companies ‘Can Fund Their Own Research’
February 24, 2026
·
2 min read
·
Tristan Manalac